UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria"

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

Erratum: Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Nature (London), 2016-05, Vol.537 (7618), p.122-122

2016

Volltextzugriff (PDF)

Fallstudien zur Analyse des Kauens Teil 3: Analyse von Höckerbewegungen

Stomatologie (Vienna, Austria), 2010-03, Vol.107 (1), p.1-7

2010

Volltextzugriff (PDF)

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Nature (London), 2016-09, Vol.537 (7618), p.122-122

2016

Volltextzugriff (PDF)

Fallstudien zur Analyse des Kauens Teil 2: Spezielle Analysemöglichkeiten

Stomatologie (Vienna, Austria), 2009-12, Vol.106 (8), p.137-148

2009

Volltextzugriff (PDF)

Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

Journal of pharmacological and toxicological methods, 2011-07, Vol.64 (1), p.7-15

2011

Volltextzugriff (PDF)

Antihypertensive Effects of a Mixed Endothelin-A- and -B-Receptor Antagonist, J-104132, Were Augmented in the Presence of an AT1-Receptor Antagonist, MK-954

Journal of cardiovascular pharmacology, 2000, Vol.36 (5 Suppl 1), p.S337-S341

2000

Volltextzugriff (PDF)

Endothelin as a target for drug development: Recent progress

Expert opinion on investigational drugs, 1994-02, Vol.3 (2), p.179-180

Siegl, Peter KS

1994

Volltextzugriff (PDF)

Assessment of sensitivity of three ECG recording methods used in dog toxicology and safety pharmacology studies

Journal of pharmacological and toxicological methods, 2010-09, Vol.62 (2), p.e4-e4

2010

Volltextzugriff (PDF)

Relevance of a standard food model in combination with electronic jaw movement recording on human mastication pattern analysis

Advances in bioscience and biotechnology, 2010-06, Vol.1 (2), p.68-78

2010

Volltextzugriff (PDF)

Models used to assess cardiovascular function in general pharmacology

Drug development research, 1994-08, Vol.32 (4), p.256-259

1994

Volltextzugriff (PDF)

Nuclear Imaging in Drug Discovery, Development, and Approval

1, 1993

Volltextzugriff (PDF)

Safety Pharmacology Assessment: How Early is Too Early (and What is Too Late)?

International journal of pharmaceutical medicine, 2007, Vol.21 (5), p.357-361

2007

Volltextzugriff (PDF)

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides. [Erratum to document cited in CA120(5):45190z]

Journal of medicinal chemistry, 1994-04, Vol.37 (7), p.1034-1034

1994

Volltextzugriff (PDF)

Angiotensin II receptor antagonists containing a phenylpyridine element

Bioorganic & medicinal chemistry letters, 1993-08, Vol.3 (8), p.1693-1696

1993

Volltextzugriff (PDF)

Imidazo[4,5-b]pyridine-based AT1/AT2 angiotensin II receptor antagonists

Bioorganic & medicinal chemistry letters, 1994-01, Vol.4 (1), p.17-22

1994

Volltextzugriff (PDF)

Monthly Updates-Cardiovascular & Renal: Epidemiology and Cardiovascular Drug Discovery Through the 1990s

Expert opinion on investigational drugs, 1995-04, Vol.4 (4), p.345-347

1995

Volltextzugriff (PDF)

Drugs for prevention of malignant ventricular arrhythmias

Expert opinion on investigational drugs, 1994-10, Vol.3 (10), p.1037-1040

1994

Volltextzugriff (PDF)

Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements

Bioorganic & medicinal chemistry letters, 1994, Vol.4 (1), p.69-74

1994

Volltextzugriff (PDF)

A new class of balanced AT1/AT2 angiotensin II antagonists : quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities

Bioorganic & medicinal chemistry letters, 1994-01, Vol.4 (1), p.81-86

1994

Volltextzugriff (PDF)

The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptors

Bioorganic & medicinal chemistry letters, 1995-07, Vol.5 (13), p.1359-1364

1995

Volltextzugriff (PDF)

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors

European journal of pharmacology, 1995-12, Vol.294 (2-3), p.439-450

1995

Volltextzugriff (PDF)

Monthly Update Cardiovascular & Renal: Treating hypertension with angiotensin II receptor antagonists: What have we learned?

Expert opinion on investigational drugs, 1995-10, Vol.4 (10), p.1013-1015

1995

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(92)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

Class III Antiarrhythmic Activity in Vivo by Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current I Ks by (R)-2-(2,4- Trifluoromethyl)-N-[2-oxo-5-phenyl- 1-(2,2,2-trifluoroethyl)-2,3-dihydro- 1H-benzo[e][1,4]diazepin-3-yl]acetamide

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria"

Erratum: Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Fallstudien zur Analyse des Kauens Teil 3: Analyse von Höckerbewegungen

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Fallstudien zur Analyse des Kauens Teil 2: Spezielle Analysemöglichkeiten

Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

Antihypertensive Effects of a Mixed Endothelin-A- and -B-Receptor Antagonist, J-104132, Were Augmented in the Presence of an AT1-Receptor Antagonist, MK-954

Endothelin as a target for drug development: Recent progress

Assessment of sensitivity of three ECG recording methods used in dog toxicology and safety pharmacology studies

Relevance of a standard food model in combination with electronic jaw movement recording on human mastication pattern analysis

Models used to assess cardiovascular function in general pharmacology

Nuclear Imaging in Drug Discovery, Development, and Approval

Safety Pharmacology Assessment: How Early is Too Early (and What is Too Late)?

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides. [Erratum to document cited in CA120(5):45190z]

Angiotensin II receptor antagonists containing a phenylpyridine element

Imidazo[4,5-b]pyridine-based AT1/AT2 angiotensin II receptor antagonists

Monthly Updates-Cardiovascular & Renal: Epidemiology and Cardiovascular Drug Discovery Through the 1990s

Drugs for prevention of malignant ventricular arrhythmias

Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements

A new class of balanced AT1/AT2 angiotensin II antagonists : quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities

The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptors

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors

Monthly Update Cardiovascular & Renal: Treating hypertension with angiotensin II receptor antagonists: What have we learned?

Aktive Filter

Suchergebnisse filtern